Novartis Pharmaceuticals Corporation has settled its litigation with the US subsidiary of Sun Pharmaceutical Industries relating to Novartis patents covering the use of certain polymorphic forms of Gleevec (imatinib mesylate), which expire in 2019 (including paediatric exclusivity). The basic compound patent for Gleevec expires in the US on July 4, 2015.
As a result of the settlement, Novartis will permit Sun Pharma’s subsidiary to market a generic version of Gleevec in the US on February 1, 2016.
The terms of the settlement agreement are otherwise confidential. Sun Pharma’s subsidiary has received tentative approval from the US Food and Drug Administration (US FDA) for its generic version of imatinib mesylate.
EP News Bureau– Mumbai
- Advertisement -
